Fewer than one in 10 people eligible to benefit from weight-loss injections including Wegovy can access them, states the World Health Organization as it publishes its inaugural guidance on the therapies.
Given in excess of 1,000,000,000 people worldwide currently obese, it is calling for increased and just availability to GLP-1 medication.
Based on forecasts, more than two billion could be obese by 2030 unless action is taken.
"The latest guidance acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major barriers to widespread access to the treatments that can assist patients in reducing substantial body mass, notes the body.
Weight-Loss Drug Supply Crisis
Despite the present best projected outlook, the supply of these medications could only cover around 100 million people – fewer than 10% of the global need, as stated by the health organization.
The guideline urges governments and firms to increase access, by strategies like patent sharing.
A patent on a key compound – the main component of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.
How Obesity Jabs Function
The injections mimick a natural hormone to reduce digestion speed, suppress the appetite and boost the sense of being full so individuals reduce food intake.
Patients typically start to lose weight after several weeks of beginning the regular doses.
Studies points to people may regain a significant portion after a year of stopping the medication, as their usual hunger come back.
To be carrying excess weight increases your risk for experiencing medical conditions, like diabetes, heart disease, brain attack, and certain malignancies.
Obesity affects individuals in every country and was responsible for millions of fatalities worldwide in 2024, as per the WHO.